by The global Automated And Closed Cell Therapy Processing Systems market size is expected to be worth around US$ 6.94 billion by 2030, according to a new report by Vision Research Reports.
The global Automated And Closed Cell Therapy Processing Systems market size was valued at US$ 715.0 million in 2020 and is anticipated to grow at a CAGR of 22.7% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38922
Table of Contents
Automated And Closed Cell Therapy Processing Systems Market Growth Factors
The growing popularity of regenerative medicines & cell therapies coupled with a range of benefits offered by automation technologies for the development of these therapies is expected to propel the market growth. In addition, the growing integration of software technologies and advanced therapy development processes is also projected to boost the market. Furthermore, rising investments by bio manufacturers for the development of cellular therapy products through rounds of series funding are anticipated to offer lucrative opportunities to or the market.
The rapid growth in the cases of COVID-19 is anticipated to play a vital role in the market growth. The pandemic has led to an increased focus on automation technologies. Moreover, the companies emphasized raising funds with an aim to develop advanced therapies and regenerative medicines to fight against COVID-19. Industry players are also concentrating on the development of new therapies, such as stem cell therapy, natural killer cell therapy, exosomes, and others.
Automated And Closed Cell Therapy Processing Systems Market Report Coverage
| Report Scope | Details |
| Market Size | US$ 6.94 Billion by 2030 |
| Growth Rate | CAGR of 22.7% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Workflow, Type, Scale |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | MiltenyiBiotec; Lonza; Fresenius Kabi; Cytiva (Danaher Corp.); BioSpherix, Ltd.; Terumo Corporation; Sartorius AG; ThermoGenesis Holdings, Inc.; Cellares, Inc.; Thermo Fisher Scientific, Inc. |
By Workflow Analysis
The expansion segment accounted for the largest revenue share of more than 35% in 2020. The growth is majorly attributed to the presence of a substantial number of products offered under this segment.
separation workflow is estimated to register the fastest CAGR during the forecast period. The cell separation process is carried out across various cellular experiments, such as molecular analysis, cellular genetic modification, production of hybridomas, and other cell research & analysis-related applications.
A growing number of research activities for these applications in academic universities and other research settings is anticipated to accelerate the segment growth. Apart from expansion and separation, the workflow segment comprises apheresis, fill-finish, cryopreservation, and others.
By Type Analysis
The non-stem cell therapy segment captured the maximum revenue share of over 61% in 2020 and is anticipated to register the fastest CAGR during the forecast period. An increasing number of product launches for non-stem cell therapy applications is expected to drive the segment growth.
Companies are extensively engaging in partnerships and collaboration with an aim to develop new regenerative medicines for the treatment of chronic conditions. Such research projects majorly focus on applications of non-stem cells, consequently driving the non-stem cell therapy segment growth.
The stem cell therapy segment is anticipated to witness a significant growth rate during the forecast period. Increasing awareness about therapeutic benefits offered by stem cell therapies and rising research activities.
By Scale Analysis
The pre-commercial/R&D scale segment dominated the global market in 2020 with a revenue share of more than 72%.At present, the market is relatively niche due to a limited number of products. Moreover, the majority of the companies are introducing their products only for research purposes.
the adoption of automated systems by research institutes due to the growing number of clinical trials for cell therapies is also projected to accelerate segment growth. The laboratories and research institutes are witnessing a range of benefits due to the adoption of automated systems.
The commercial-scale segment is expected to register the fastest CAGR from 2021 to 2028. The increasing prevalence of chronic conditions, such as cancer, is encouraging companies to develop enhanced cell-therapy-based therapeutic platforms.
By Regional Analysis
North America accounted for the largest revenue share of over 45.5%in 2020. This high share was majorly attributed to the increased technological adoption for cell therapy processing and emphasis on high precision & production throughput.
Growing investments by market players as well as research institutes are also expected to play a vital role in the region’s growth. Growing investments by market players as well as research institutes are also expected to play a vital role in the region’s growth.
Over the recent year, a series of fully automated platforms were introduced across European countries, which is capable of supporting the bioprocess workflows from start to end.
Read also @ Dermatology Excimer Laser Market Estimated to Cross US$ 2.03 Bn by 2030
Major Key Players Covered in The Automated And Closed Cell Therapy Processing Systems Market Report include
- MiltenyiBiotec
- Lonza
- Fresenius Kabi
- Cytiva (Danaher Corp.)
- BioSpherix, Ltd.
- Terumo Corporation
- Sartorius AG
- ThermoGenesis Holdings, Inc.
- Cellares Inc.
- Thermo Fisher Scientific, Inc.
Automated And Closed Cell Therapy Processing Systems Market Segmentation
- By Workflow
- Separation
- Expansion
- Apheresis
- Fill- Finish
- Cryopreservation
- Others
- By Type
- Stem Cell Therapy
- Non-Stem Cell Therapy
- By Scale
- Pre-commercial/R&D Scale
- Commercial Scale
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Automated And Closed Cell Therapy Processing Systems Market Snapshot
Chapter 4. Automated And Closed Cell Therapy Processing Systems Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Automated And Closed Cell Therapy Processing Systems Market Dynamics Analysis and Trends
5.1. Automated And Closed Cell Therapy Processing Systems Market Dynamics
5.1.1. Automated And Closed Cell Therapy Processing Systems Market Drivers
5.1.2. Automated And Closed Cell Therapy Processing Systems Market Restraints
5.1.3. Automated And Closed Cell Therapy Processing Systems Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Automated And Closed Cell Therapy Processing Systems Market, By Workflow
7.1. Automated And Closed Cell Therapy Processing Systems Market, by Workflow, 2021-2030
7.1.1. Separation
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Expansion
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Apheresis
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Fill- Finish
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. Cryopreservation
7.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Automated And Closed Cell Therapy Processing Systems Market, By Type
8.1. Automated And Closed Cell Therapy Processing Systems Market, by Type, 2021-2030
8.1.1. Stem Cell Therapy
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Non-Stem Cell Therapy
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Automated And Closed Cell Therapy Processing Systems Market, By Scale
9.1. Automated And Closed Cell Therapy Processing Systems Market, by Scale, 2021-2030
9.1.1. Pre-commercial/R&D Scale
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Commercial Scale
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Automated And Closed Cell Therapy Processing Systems Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.1.2. Market Revenue and Forecast, by Type (2017-2030)
10.1.3. Market Revenue and Forecast, by Scale (2017-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Type (2017-2030)
10.1.4.3. Market Revenue and Forecast, by Scale (2017-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.1.5.2. Market Revenue and Forecast, by Type (2017-2030)
10.1.5.3. Market Revenue and Forecast, by Scale (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.2.2. Market Revenue and Forecast, by Type (2017-2030)
10.2.3. Market Revenue and Forecast, by Scale (2017-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Type (2017-2030)
10.2.4.3. Market Revenue and Forecast, by Scale (2017-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Type (2017-2030)
10.2.5.3. Market Revenue and Forecast, by Scale (2017-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Type (2017-2030)
10.2.6.3. Market Revenue and Forecast, by Scale (2017-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.2.7.2. Market Revenue and Forecast, by Type (2017-2030)
10.2.7.3. Market Revenue and Forecast, by Scale (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.3.2. Market Revenue and Forecast, by Type (2017-2030)
10.3.3. Market Revenue and Forecast, by Scale (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Type (2017-2030)
10.3.4.3. Market Revenue and Forecast, by Scale (2017-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Type (2017-2030)
10.3.5.3. Market Revenue and Forecast, by Scale (2017-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Type (2017-2030)
10.3.6.3. Market Revenue and Forecast, by Scale (2017-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.3.7.2. Market Revenue and Forecast, by Type (2017-2030)
10.3.7.3. Market Revenue and Forecast, by Scale (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.4.2. Market Revenue and Forecast, by Type (2017-2030)
10.4.3. Market Revenue and Forecast, by Scale (2017-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Type (2017-2030)
10.4.4.3. Market Revenue and Forecast, by Scale (2017-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Type (2017-2030)
10.4.5.3. Market Revenue and Forecast, by Scale (2017-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Type (2017-2030)
10.4.6.3. Market Revenue and Forecast, by Scale (2017-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.4.7.2. Market Revenue and Forecast, by Type (2017-2030)
10.4.7.3. Market Revenue and Forecast, by Scale (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.5.2. Market Revenue and Forecast, by Type (2017-2030)
10.5.3. Market Revenue and Forecast, by Scale (2017-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Type (2017-2030)
10.5.4.3. Market Revenue and Forecast, by Scale (2017-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Workflow (2017-2030)
10.5.5.2. Market Revenue and Forecast, by Type (2017-2030)
10.5.5.3. Market Revenue and Forecast, by Scale (2017-2030)
Chapter 11. Company Profiles
11.1. MiltenyiBiotec
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Lonza
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Fresenius Kabi
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Cytiva (Danaher Corp.)
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. BioSpherix, Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Terumo Corporation
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Sartorius AG
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. ThermoGenesis Holdings, Inc
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Cellares Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Thermo Fisher Scientific, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38922
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
